CCTG Clinical Trials
Public Trial Select
Member Trial Select
TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancerClinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Donation helps advance research
The establishment of the Britton Smith Foundation Clinical Trials Fund
At the Canadian Cancer Society, our vision to create a world in which no Canadian fears cancer is only achievable if we work collectively with people united by the same goals. With nearly one in two Canadians expected to be diagnosed with cancer in their lifetime, cancer affects us all.
At the cancer society, we believe research is the best way to accelerate progress so that more cancers can be prevented, and more people will not just survive cancer, but live longer and fuller lives.
Today more than 60 per cent of Canadians diagnosed with cancer will survive, compared with about 25 per cent in the 1940s, because of the advancements discovered through research. We are determined to empower people with cancer and ensure there are new treatment options for Canadians. One way we do this is through our support of life-saving clinical trials.
A thank you from Doug Kane, senior manager, Canadian Cancer Society FLA & The Waterways Community Office
More >>
Cell Therapy’s Promise for Canadians Must Include Access
An emerging form of immunotherapy, called adoptive cell transfer, has the potential to transform the way in which cancers are treated.
More >>
Palliative and supportive care presentation at ESMO 2019
Approximately a fifth of patients participating in phase III breast, lung, or colorectal cancer clinical trials conducted by CCTG also used complementary medicines.
More >>
Palliative and supportive care presentation at ESMO 2019
Approximately a fifth of patients participating in phase III breast, lung, or colorectal cancer clinical trials conducted by CCTG also used complementary medicines.
More >>
Innovative study advances personalized medicine for prostate cancer patients
CCTG IND224 is a new clinical trial, opening across Canada, is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world.
More >>
CCTG LY16 | RELEVANCE published in New England Journal of Medicine
The results of the CCTG LY16 trial of Rituxmab plus Lenalidomide in Advanced Untreated Follicular Lymphoma (RELEVANCE), recently published in New England Journal of Medicine, has the potential to offer a new treatment option to lymphoma patients, that does not require chemotherapy.
More >>
The rise of precision medicine
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
More >>Planned trials
CRC9
Circulating Tumor DNA as a Predictive Marker for Response to Chemotherapy in Pts with Stage II Colon Ca
CEC7
Recently activated
The rise of precision medicine
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
More >>
TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancer
Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.
More >>
Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide
Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.
More >>
Canadian Cancer Research Alliance announces award winners
Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham will receive the Exceptional Leadership in Patient Involvement in Cancer award.
More >>Publications
CO.28: Neoadjuvant Chemotherapy, Excision and Observation (NEO) for early rectal cancer
J Clin Oncol 37: TPS724 - TPS724, 2019
Kennecke HF;Brown CJ;Auer R;Drolet S;Eng C;Gordon VL;Hochman DJ;Moloo H;Wei AC;Chan K;Montenegro A;Loree JM;Tu D;Jonker DJ;
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study (ONLINE)
Invest New Drugs , 2019
Lapointe S;Mason W;MacNeil M;Harlos C;Tsang R;Sederias J;Luchman HA;Weiss S;Rossiter JP;Tu D;Seymour L;Smoragiewicz M;
Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201) (ONLINE)
Clin Cancer Res : clincanres, 2019
Luke JJ;Olson DJ;Allred JB;Strand CA;Bao R;Zha Y;Carll T;Labadie BW;Bastos BR;Butler MO;Hogg D;Munster PN;Schwartz GK;
Optimizing whole brain radiotherapy dose and fractionation: Results from a prospective phase III trial (NCCTG N107C (Alliance)/CEC.3) (ONLINE)
International Journal of Radiation Oncology*Biology*Physics , 2019
Trifiletti DM;Ballman KV;Brown PD;Anderson SK;Carrero XW;Cerhan JH;Whitton AC;Greenspoon J;Parney IF;Laack NN;Ashman JB;Bahary JP;Hadjipanayis CG;Urbanic JJ;Barker FG;Farace E;Khuntia D;Giannini C;Buckner JC;Galanis E;Roberge D;
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial
J Clin Oncol 37: 2338 - 2348, 2019
Muss HB;Polley MY;Berry DA;Liu H;Cirrincione CT;Theodoulou M;Mauer AM;Kornblith AB;Partridge AH;Dressler LG;Cohen HJ;Kartcheske PA;Perez EA;Wolff AC;Gralow JR;Burstein HJ;Mahmood AA;Sutton LM;Magrinat G;Parker BA;Hart RD;Grenier D;Hurria A;Jatoi A;Norton L;Hudis CA;Winer EP;Carey L;
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
N Engl J Med 380: 2395 - 2405, 2019
Sparano JA;Gray RJ;Ravdin PM;Makower DF;Pritchard KI;Albain KS;Hayes DF;Geyer CE;Dees EC;Goetz MP;Olson JA;Lively T;Badve SS;Saphner TJ;Wagner LI;Whelan TJ;Ellis MJ;Paik S;Wood WC;Keane MM;Gomez Moreno HL;Reddy PS;Goggins TF;Mayer IA;Brufsky AM;Toppmeyer DL;Kaklamani VG;Berenberg JL;Abrams J;Sledge GW;
Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer
Pharmacogenetics and Genomics 29: 183 - 191, 2019
Ingle JN;Kalari KR;Momozawa Y;Kubo M;Furukawa Y;Shepherd LE;Ellis MJ;Goss PE;Barman P;Carlson EE;Sinnwell JP;Tang X;Goetz MP;Chen BE;Cairns J;Weinshilboum RM;Wang L;
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial (ONLINE)
JAMA Oncology , 2019
Sparano JA;Gray RJ;Makower DF;Albain KS;Saphner TJ;Badve SS;Wagner LI;Kaklamani VG;Keane MM;Gomez HL;Reddy PS;Goggins TF;Mayer IA;Toppmeyer DL;Brufsky AM;Goetz MP;Berenberg JL;Mahalcioiu C;Desbiens C;Hayes DF;Dees EC;Geyer CE Jr;Olson JA;Wood WC;Lively T;Paik S;Ellis MJ;Abrams J;Sledge GW;